arrow
K

Kitsada Wudhikarn

chulalongkorn university
H指数:24
被引数:2,472

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

Idecabtagene vicleucel治疗后100天内感染及其对复发/难治性多发性骨髓瘤患者生存的影响:CIBMTR分析

2026-06-270
PRE
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Mucosal-Associated Lymphoid Tissue Lymphoma in Southeast Asia: A 15-Year Retrospective Multicenter Study

黏膜相关淋巴组织淋巴瘤在东南亚:一项为期15年的回顾性多中心研究

2025-11-250
OA
Optimizing Markers for Chronic Lymphocytic Leukemia Diagnosis by Flow Cytometry: Results From the Nationwide Thai Lymphoma Study Group

通过流式细胞术优化慢性淋巴细胞白血病的诊断标志物:来自泰国全国淋巴瘤研究组的结果

2025-10-080
OAAI
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma

新型合并症指数与大型B细胞淋巴瘤嵌合抗原受体T细胞治疗后生存期的关联

2025-08-180
OAAI
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis

tisagenleucel治疗后B-Cell ALL患者感染的实时世界结局:一项CIBMTR分析

2025-08-050
OAAI
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

CD19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤后的感染:CIBMTR的真实世界分析

2025-05-300
OAAI
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry

真实世界(RW)结局:Brexucabtagene autoleucel(Brexu-Cel)治疗具有高风险特征及既往治疗史患者的复发或难治性B细胞急性淋巴细胞白血病(R/R B-ALL)结局;来自CIBMTR®登记数据的更新证据

BLOOD
IF23.1
2024-11-051
PRE
Detection of MRD Using IGH Assay By NGS after Second Cycle of Chemotherapy in Adult B-Lymphoblastic Leukemia Predicts Poor Clinical Outcomes: Results from a Multicenter Study

成人B淋巴细胞急性白血病在第二化疗周期后使用NGS通过IGH检测微小残留病预测不良临床结局:一项多中心研究的结果

BLOOD
IF23.1
2024-11-050
PRE
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis
LEUKEMIA
IF13.4
2024-05-150
PRE
A Day 14 Endpoint for Acute GVHD Clinical Trials
2024-04-012
OAAI
Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group
2023-09-182
PRE
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

CD19 CAR T细胞治疗时无残留淋巴瘤的DLBCL患者的低毒性和良好的预后

2023-07-0317
OAAI
Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)

在复发和/或难治性弥漫性大b细胞淋巴瘤患者的现实环境中,含polatuzumab vedotin的方案的结局: 来自泰国淋巴瘤研究组 (TLSG) 的匹配对照分析

2023-05-185
PRE
Germline HAVCR2 mutations and their relation to the clinical spectrum of subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis: results from a multicenter study and meta-analysis
2023-04-1310
OAAI